<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7067438/results/search/test_trace/results.xml">
  <result pre="controlled trial of a combination of antiviral and nonsteroidal anti-inflammatory" exact="treatment" post="in a bovine model of respiratory syncytial virus infection"/>
  <result pre="anti-inflammatory treatment in a bovine model of respiratory syncytial virus" exact="infection" post="RCT of an antiviral and ibuprofen in bovine respiratory"/>
  <result pre="of an antiviral and ibuprofen in bovine respiratory syncytial virus" exact="infection" post="http://orcid.org/0000-0003-4059-7115WalshPaulConceptualizationData curationFormal analysisFunding acquisitionInvestigationMethodologyProject administrationSupervisionValidationVisualizationWriting – original draftWriting –"/>
  <result pre="the two initiated at 3 or 5 days after artificial" exact="infection" post="with bovine RSV in 36 five to six-week-old Holstein"/>
  <result pre="We estimated the average effect for each drug and compared" exact="treatment" post="arms using mixed effects models. Results We found a"/>
  <result pre="a significant decrease in clinical scores only in the combined" exact="treatment" post="arms. This benefit was greater when treatment was initiated"/>
  <result pre="in the combined treatment arms. This benefit was greater when" exact="treatment" post="was initiated at 3 days rather than 5 days"/>
  <result pre="was initiated at 3 days rather than 5 days post" exact="infection" post="with decreased clinical scores and lower respiratory rates at"/>
  <result pre="of morbidity and hospitalization worldwide.[1–3] Bovine RSV causes an analogous" exact="infection" post="in bovine calves and often triggers bovine respiratory disease"/>
  <result pre="human RSV. The clinical and immunological manifestations are similar, natural" exact="infection" post="fails to induce immunity in both species, and enhanced"/>
  <result pre="(Ovis aries)[10] and cotton rat (Sigmodon hispidus) models of RSV" exact="infection" post="[9]. This activity is concentrated in bronchial and bronchiolar"/>
  <result pre="these studies is that some of the pathology of RSV" exact="infection" post="is self-inflicted by the hosts’ immune system and this"/>
  <result pre="this might be decreased with NSAIDs. Pretreatment and very early" exact="treatment" post="with anti-RSV antibodies, modestly decreases clinical findings and lung"/>
  <result pre="against RSV in human infants [13]but is ineffective as antiviral" exact="treatment" post="once infection has occurred.[14] Experiments in a cotton rat"/>
  <result pre="in human infants [13]but is ineffective as antiviral treatment once" exact="infection" post="has occurred.[14] Experiments in a cotton rat model of"/>
  <result pre="immunomodulation with NSAIDs or steroids did improve clinical outcomes following" exact="infection" post="in a way that monotherapy did not. [9, 15]"/>
  <result pre="scores, viral shedding, and histology using the same bovine RSV" exact="infection" post="model described here. However, these effects were markedly attenuated"/>
  <result pre="model described here. However, these effects were markedly attenuated when" exact="treatment" post="was started on day 3 compared with day 1"/>
  <result pre="3 compared with day 1 post-inoculation. [16] Although anti-RSV antibodies" exact="treatment" post="represent a very different approach to FPI treatment, the"/>
  <result pre="different approach to FPI treatment, the need for very early" exact="treatment" post="raise the question as to whether combining an NSAID"/>
  <result pre="of these initiated at three or five days after artificial" exact="infection" post="with bovine RSV. The study was approved by the"/>
  <result pre="each replicate into an ‘A’ and ‘B’ group. Each drug" exact="treatment" post="arm contained a group A and a group B"/>
  <result pre="charts as bull charts were not available.[26] Humane endpoints for" exact="infection" post="with bovine RSV were established prior to initiation of"/>
  <result pre="parameters measured. The animals were randomized to one of six" exact="treatment" post="arms with varying start times for first dose of"/>
  <result pre="singly administered beginning on the day following experimental bovine RSV" exact="infection" post="and beginning on day 3 after infection for FPI,"/>
  <result pre="experimental bovine RSV infection and beginning on day 3 after" exact="infection" post="for FPI, [22, 27] we did not include drug"/>
  <result pre="clinical examinations were also performed in the days prior to" exact="infection" post="with bovine RSV. We also compared the effects of"/>
  <result pre="infection with bovine RSV. We also compared the effects of" exact="treatment" post="on clinical score without the temperature component, and on"/>
  <result pre="calves’ nostrils. For this purpose, calf nasal swabs collected before" exact="infection" post="and daily after infection were extracted in 400 μl"/>
  <result pre="purpose, calf nasal swabs collected before infection and daily after" exact="infection" post="were extracted in 400 μl of RNALater Stabilization solution"/>
  <result pre="separate spline function for each outcome. We analyzed each drug" exact="treatment" post="arm, i.e. arm 1 to 6, encoded as dummy"/>
  <result pre="if there was a benefit beyond antipyresis in the ibuprofen" exact="treatment" post="arms. We used the same approach when estimating drug"/>
  <result pre="graphed. We present un-interacted estimates of the effect of each" exact="treatment" post="arm on the clinical score to facilitate interpretation. We"/>
  <result pre="scores. We graphed the hazard ratio for time to each" exact="treatment" post="group to first the top quartile of clinical score"/>
  <result pre="We started the risk period at day 0 for each" exact="treatment" post="group to avoid immortal time bias. Our replicates are"/>
  <result pre="protocol. Two, one in the ibuprofen starting on day 3" exact="treatment" post="arm, and one in the placebo arm were euthanized"/>
  <result pre="and all received their assigned treatments. Baseline characteristics for each" exact="treatment" post="arm are shown in Table 2. 10.1371/journal.pone.0230245.t002Table 2 Baseline"/>
  <result pre="charts.[26] Fig 2 shows the mean clinical scores for each" exact="treatment" post="arm by replicate, Fig 3 shows the same scores"/>
  <result pre="after excluding the fever component from the clinical score. Our" exact="treatment" post="arm analysis showed greater benefit in clinical scores and"/>
  <result pre="showed greater benefit in clinical scores and respiratory rate when" exact="treatment" post="was initiated earlier, and the combination of ibuprofen and"/>
  <result pre="was better than either drug alone. The benefit of ibuprofen" exact="treatment" post="demonstrated by decreased clinical scores in the ibuprofen only"/>
  <result pre="in Table 3. Fig 2 Daily mean clinical scores by" exact="treatment" post="arm. Clinical score by treatment arm. FPI; fusion protein"/>
  <result pre="Daily mean clinical scores by treatment arm. Clinical score by" exact="treatment" post="arm. FPI; fusion protein inhibitor. Fig 3 Clinical score"/>
  <result pre="arm. FPI; fusion protein inhibitor. Fig 3 Clinical score by" exact="treatment" post="arm excluding the temperature component. FPI; fusion protein inhibitor."/>
  <result pre="temperature component. FPI; fusion protein inhibitor. 10.1371/journal.pone.0230245.t003Table 3 Results by" exact="treatment" post="arm. Treatment arm Clinical Score 95% CI Clinical Score"/>
  <result pre="appeared to dominate with respect to viral load. Analysis by" exact="treatment" post="arm showed greater benefit when treatment was initiated earlier,"/>
  <result pre="viral load. Analysis by treatment arm showed greater benefit when" exact="treatment" post="was initiated earlier, and the combination of ibuprofen and"/>
  <result pre="changes in weight-for-age centile were not statistically significantly different between" exact="treatment" post="arms. These data are shown in Fig 5. Fig"/>
  <result pre="in Fig 5. Fig 5 Change in centile weight-for-age by" exact="treatment" post="arm. Ibup; ibuprofen, FPI; fusion protein inhibitor. (Missing data"/>
  <result pre="the FPI-only day 5 arm). The hazard ratios for each" exact="treatment" post="group entering the top quartile of clinical score using"/>
  <result pre="score using Cox proportional hazard models were lower in all" exact="treatment" post="groups than placebo but the differences were significant only"/>
  <result pre="placebo but the differences were significant only in the combined" exact="treatment" post="arms (Table 4). The cumulative hazards curves are shown"/>
  <result pre="seen when FPI alone was used. Prior experimental evidence that" exact="treatment" post="with NSAIDs decreases illness when initiated after RSV infection"/>
  <result pre="that treatment with NSAIDs decreases illness when initiated after RSV" exact="infection" post="has occurred is limited. Richardson et al found some"/>
  <result pre="have advanced current knowledge (1) by determining that initiation of" exact="treatment" post="up to five days after inoculation is beneficial and"/>
  <result pre="in human infants. Our work extends prior work on antiviral" exact="treatment" post="for RSV. Pretreatment and early treatment with antiviral drugs"/>
  <result pre="prior work on antiviral treatment for RSV. Pretreatment and early" exact="treatment" post="with antiviral drugs decreases clinical findings and lung histopathology."/>
  <result pre="lung histopathology. Treatment benefit decreases with time from inoculation initiated" exact="treatment" post="on first detection of viral shedding by PCR again"/>
  <result pre="benefit decreases with time from inoculation initiated treatment on first" exact="detection" post="of viral shedding by PCR again making antivirals of"/>
  <result pre="as measured by, however viral shedding was minimally decreased when" exact="treatment" post="was started on day 3 post-inoculation.[16] Our results for"/>
  <result pre="are anti-inflammatory and antipyretic in the context of bacterial lung" exact="infection" post="that frequently complicates bovine RSV.[31] Similarly, the combination of"/>
  <result pre="decreases the severity of porcine respiratory disease complex. Bacterial super" exact="infection" post="complicates human RSV in at least 40% of those"/>
  <result pre="results in bovines could potentially decrease antibiotic use if the" exact="diagnosis" post="of bovine RSV can be made early enough to"/>
  <result pre="treated at the first appearance of RSV shedding following artificial" exact="infection" post="with human RSV do benefit from FPI.[17] In infants"/>
  <result pre="wheezing.[35] We speculate that delaying the first episode of RSV" exact="infection" post="until infants’ Th2 skew has decreased may decrease the"/>
  <result pre="Indeed, Gershwin et al previously showed using this bovine RSV" exact="infection" post="model that infected calves are more predisposed to production"/>
  <result pre="to production of IgE antibodies against aerosolized ovalbumin during active" exact="infection" post="than are uninfected calves [36] and a similar phenomenon"/>
  <result pre="of dual antiviral and anti-inflammatory or even a more multifaceted" exact="treatment" post="regimen for RSV has been proposed before.[15] [38] [39]"/>
  <result pre="glucocorticoid, with palivizumab, a monoclonal antibody decreased lung histopathology when" exact="treatment" post="was started on the third day following inoculation in"/>
  <result pre="response of outbred animals. This makes it harder to detect" exact="treatment" post="differences when present. More nuanced and complex outcomes, for"/>
  <result pre="both drugs was effective at 3 and 5 days after" exact="infection" post="with earlier initiation leading to better outcomes. Supporting information"/>
  <result pre="study of altered clinical reactivity to respiratory syncytial (RS) virus" exact="infection" post="in children previously vaccinated with an inactivated RS virus"/>
  <result pre="OttoliniMG, PletnevaL, BoukhvalovaM, ZhangS, VogelSN, et al.Respiratory Syncytial Virus (RSV)" exact="infection" post="induces cyclooxygenase 2: A potential target for RSV therapy."/>
  <result pre="administered in drinking water at a low dose for the" exact="treatment" post="of porcine respiratory disease complex. J Anim Sci. 2013;91(9):4469–75."/>
  <result pre="syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus" exact="infection" post="in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3"/>
  <result pre=".9738173 14AlansariK, ToaimahFH, AlmatarDH, El TatawyLA, DavidsonBL, QusadMIM. Monoclonal antibody" exact="treatment" post="of RSV bronchiolitis in young infants: A Randomized Trial."/>
  <result pre="Randomized placebo controlled trial of ibuprofen for Respiratory Syncytial Virus" exact="infection" post="in a bovine model. PLoS One. 2016;11(4):e0152913 Epub 2016/04/13."/>
  <result pre="of flunixin, carprofen and ketoprofen as adjuncts to the antibacterial" exact="treatment" post="of bovine respiratory disease. Vet Rec. 2003;152(13):392–4. Epub 2003/04/17."/>
  <result pre="in pulmonary efferent lymph collected after ovalbumin inhalation during experimental" exact="infection" post="of calves with bovine respiratory syncytial virus. American Journal"/>
  <result pre="2000;182(5):1326–30. 39RosenbergHF, DomachowskeJB. Inflammatory responses to respiratory syncytial virus (RSV)" exact="infection" post="and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem."/>
  <result pre="an ultra-potent antibody for the prevention of respiratory syncytial virus" exact="infection" post="in the upper and lower respiratory tract. J Mol"/>
  <result pre="10.1086/314523 .9815203 46SandersSL, AgwanS, HassanM, van DrielML, Del MarCB. Immunoglobulin" exact="treatment" post="for hospitalised infants and young children with respiratory syncytial"/>
 </snippets>
</snippetsTree>
